<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332904</url>
  </required_header>
  <id_info>
    <org_study_id>CD-0606-HH-UH-DK</org_study_id>
    <nct_id>NCT00332904</nct_id>
  </id_info>
  <brief_title>Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis</brief_title>
  <acronym>PEKASYS</acronym>
  <official_title>Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The studyÂ´s purpose is to investigate the effect of beta blockade or aldosterone antagonist
      therapy on oxygenation, peripheral and cardiac hemodynamics and humoral systems, in patients
      with liver cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardio-pulmonal complications to patients with liver cirrhosis and portal hypertension
      determine the patients' prognosis. Most patients have hemodynamical changes in circulation
      with increased cardiac output and decreased systolic function in stress. Endothelial
      dysfunction is a parameter for bad prognosis in cardiovascular disease. The
      Renin-angiotensin-aldosterone-system plays an important role in natrium and volume
      regulation. Descriptions of changes in the peripheral circulation and oxygenation have been
      deficient up to now.

      Patients with liver cirrhosis and portal hypertension are betablockers and/or aldosterone
      antagonists routine treatment - effects on peripheral hemodynamics and oxygenation in
      relation to central hemodynamic changes are deficient.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>effect of treatment on hemodynamic and cardiac parameters</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>beta</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with liver cirrhosis, treated with betablocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>spiron</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with liver cirrhosis, treated with aldosterone antagonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients with liver cirrhosis, no treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment</description>
    <arm_group_label>beta</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spironolactone</intervention_name>
    <description>tablet 200 mg pr. day in 3 weeks, evt. dose adjustment</description>
    <arm_group_label>spiron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver cirrhosis

          -  Clinical indication for treatment with betablocker or aldosterone antagonist

          -  Must not have been treated earlier with betablocker or aldosterone antagonist

          -  Must have been alcohol abstinent for more than 4 weeks

        Exclusion Criteria:

          -  Gastrointestinal bleeding in the last 2 weeks

          -  Encephalopathy &gt; grade 1

          -  Acute medical conditions

          -  Malignant disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soeren Moeller, MD, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Physiology and Nuclear Medicine, and Department for Gastrointestinal Medicine, Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2006</study_first_submitted>
  <study_first_submitted_qc>May 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2006</study_first_posted>
  <last_update_submitted>June 3, 2010</last_update_submitted>
  <last_update_submitted_qc>June 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christine Duemcke, MD</name_title>
    <organization>Hvidovre Hospital</organization>
  </responsible_party>
  <keyword>betablocker</keyword>
  <keyword>aldosterone antagonist</keyword>
  <keyword>peripheral haemodynamics</keyword>
  <keyword>cardiac haemodynamics</keyword>
  <keyword>oxygenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
    <mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

